Valued at USD 312.62 million in 2025, the Residual DNA Testing Market is projected to reach USD 329.66 million in 2026 and USD 519.69 million by 2034, growing at a CAGR of 5.9% during the forecast period 2026–2034. Residual DNA testing measures the presence and concentration of host-cell DNA in biopharmaceuticals, where host cells include mammalian Chinese hamster ovary cells, bacteria and yeast cultures. Regulators control permissible levels, making testing essential to biologic drug safety and to quality assurance across upstream and downstream processes. Prominent players include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., PerkinElmer Inc., Charles River Laboratories International Inc., Lonza Group AG, SGS SA, Eurofins Scientific SE, and QIAGEN N.V.

Technology Landscape in the Residual DNA Testing Market

The PCR segment held a dominant 54.95% share in 2025 due to the use of qPCR residual DNA testing for quality control. It remains the leading method in biopharmaceutical manufacturing owing to established procedures, regulatory acceptance, lower cost, faster processing and fewer validation steps. Automation of testing equipment is increasingly widespread, and high-throughput systems support large-scale biologics production. Digital PCR DNA quantification offers very high sensitivity and accuracy, with greater precision at low DNA concentrations, though at moderate-to-high cost and moderate validation complexity. Next generation sequencing DNA testing delivers ultra-high sensitivity and deep sequence insight, but with longer turnaround, high cost and high validation complexity. The NGS segment is nevertheless expected to grow at the highest CAGR over the forecast period owing to demand for sensitive detection, supported by growth in advanced therapies.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/residual-dna-testing-market

Product, Service and Sample Insights

Kits accounted for the largest product and service share in 2025, reported at 15.5%, owing to rising demand for standard, pre-packaged residual DNA testing kits. Biopharmaceutical organizations are prioritizing standardization and validation of workflows, and ease of use and regulatory compliance support adoption. By sample type, the in-process segment held the largest share in 2025 as manufacturers emphasize in-process monitoring to detect residuals early, while the final product segment is projected to grow fastest owing to strict regulatory requirements for product release testing. Biotech was the largest end-user segment in 2025, as companies prioritize quality control and regulatory compliance alongside R&D activities.

Regional Outlook

North America held 43.72% of revenue in 2025, driven by strong biologics production and strict regulatory requirements for product safety. The FDA imposes stringent regulations on residual host-cell DNA in biologicals and vaccines, and the US accounts for approximately 80% of regional revenue thanks to advanced biopharmaceutical infrastructure and high use of qPCR. Europe held the second-largest share, backed by a robust regulatory environment and rising biologics production, with steady demand in Germany, France and the UK. Asia Pacific is projected to grow at a 6.5% CAGR during the forecast period as India and China develop biomanufacturing plants and quality control systems; in May 2025, Gene Solutions collaborated with NEWCL to provide genetic testing in Taiwan using NGS lab services.

Restraints, Digital Opportunity and Competition

The high cost of advanced testing technologies limits adoption among small and medium-sized manufacturers, as equipment, operation and validation costs add financial burden. Digital tools and AI-based analytics improve precision, reduce operator errors and cut processing time; in January 2026, Google DeepMind developed AlphaGenome, an AI technology advancing genetic studies. The Residual DNA Testing industry is moderately concentrated, with instrument providers, reagent suppliers and contract research organizations competing on detection sensitivity, regulatory compliance and turnaround time, while players concentrate their efforts on PCR and sequencing technologies. The industry is expected to become highly competitive owing to growth in biological drug manufacture and stringent regulations, with emphasis on sensitive test procedures and automation for better efficiency.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market